Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592275 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
NCT05592275: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT05592275 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 332 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (150% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05592275, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
Primary Outcome
Results are estimated using least squares (LS) mean from the mixed model repeated measures (MMRM) model: Change from baseline = Baseline + Strata + Gender + Treatment + Time + Treatment\*Time + Baseline\*Treatment.
Interventions
- DRUG Placebo
- DRUG LY3540378
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2023-02-03 |
| Est. Completion | 2025-01-22 |
| Phase | Phase 2 |
Why NCT05592275 stopped before completion
NCT05592275 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (150% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05592275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05592275 about?
NCT05592275 is a clinical study titled "A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)". The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
What is the current status of trial NCT05592275?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2023-02-03. Estimated completion is 2025-01-22.
What interventions are being tested in trial NCT05592275?
The interventions under investigation include: Placebo (DRUG), LY3540378 (DRUG).
Who is sponsoring clinical trial NCT05592275?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05592275's enrollment target sits among peer trials
332 144th of 2000 higher than 1,856 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI